A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Gray, Joe ^a   Chattopadhyay, Dipankar ^a   Beale, Gary S ^a   Patman, Gillian L ^a   Miele, Luca ^a,b   King, Barry P ^a   Stewart, Stephen ^c   Hudson, Mark ^c   Day, Christopher P ^a,c   Manas, Derek M ^c   Reeves, Helen L ^a,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; CD5 ANTIGEN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; ISOPROTEIN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; TWO DIMENSIONAL GEL ELECTROPHORESIS; BLOOD; FATTY LIVER; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; RISK;

AGED; CARCINOMA, HEPATOCELLULAR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; PROTEOMICS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 69249148700     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-271     Document Type: Article

References (34)

1. Neuschwander-Tetri BA Caldwell SH Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference Hepatology 2003, 37(5):1202-1219. 10.1053/jhep.2003.50193 12717402
2. Parkin DM Bray F Ferlay J Pisani P Estimating the world cancer burden: Globocan 2000 Int J Cancer 2001, 94(2):153-156. 10.1002/ijc.1440 11668491
3. Bruix J Llovet JM Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 2002, 35(3):519-524. 10.1053/ jhep.2002.32089 11870363
4. Deuffic S Poynard T Buffat L Valleron AJ Trends in primary liver cancer Lancet 1998, 351(9097):214-215. 10.1016/S0140-6736(05)78179-4 9449893
5. Bosch FX Ribes J Diaz M Cleries R Primary liver cancer: Worldwide incidence and trends Gastroenterology 2004, 127(5 Suppl 1):S5-S16. 10.1053/j.gastro.2004.09.011 15508102
6. Halfon P Imbert-Bismut F Messous D Antoniotti G Benchetrit D Cart-Lamy P Delaporte G Doutheau D Klump T Sala M et al A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease Comp Hepatol 2002, 1:1-3. 10.1186/1476-5926-1-3 149429 12537583
7. Angulo P Hui JM Marchesini G Bugianesi E George J Farrell GC Enders F Saksena S Burt AD Bida JP et al The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD Hepatology 2007, 45(4):846-854. 10.1002/hep.21496 17393509
8. Guha IN Parkes J Roderick P Chattopadhyay D Cross R Harris S Kaye P Burt AD Ryder SD Aithal GP et al Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers Hepatology 2008, 47(2):455-460. 10.1002/hep.21984 18038452
9. Bedogni G Miglioli L Masutti F Tiribelli C Marchesini G Bellentani S Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study Hepatology 2005, 42(1):44-52. 10.1002/ hep.20734 15895401
10. Sherman M Alphafetoprotein: An obituary J Hepatol 2001, 34(4):603-605. 10.1016/S0168-8278(01)00025-3 11394662
11. Bruix J Sherman M Llovet JM Beaugrand M Lencioni R Burroughs AK Christensen E Pagliaro L Colombo M Rodes J Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 2001, 35(3):421-430. 10.1016/S0168-8278(01)00130-1 11592607
12. Brunt EMJC Di Bisceglie AM Neuschwander-Tetri BA Bacon BR Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions Am J Gastroenterol 1999, 94(9):2467-2474. 10.1111/ j.1572-0241.1999.01377.x 10484010
13. Miele L Beale G Patman G Nobili V Leathart J Grieco A Abate M Friedman SL Narla G Bugianesi E et al The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease Gastroenterology 2008, 135(1):282-291, e281. 10.1053/ j.gastro.2008.04.004 18515091
14. Wilson JF Liver cancer on the rise Ann Intern Med 2005, 142(12 Pt 1):1029-1032. 15968025
15. Giannelli G Fransvea E Trerotoli P Beaugrand M Marinosci F Lupo L Nkontchou G Dentico P Antonaci S Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients Clin Chim Acta 2007, 383(12):147-152. 10.1016/ j.cca.2007.05.014 17582392
16. Beale G Chattopadhyay D Gray J Stewart S Hudson M Day C Trerotoli P Giannelli G Manas D Reeves H AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease BMC cancer 2008, 8:200. 10.1186/ 1471-2407-8-200 2488355 18638391
17. Rigamonti C Fraquelli M Do not trivialize the Fibroscan examination, value its accuracy J Hepatol 2007, 46(6):1149. 10.1016/ j.jhep.2007.03.010 17445941
18. Yoneda M Yoneda M Mawatari H Fujita K Endo H Iida H Nozaki Y Yonemitsu K Higurashi T Takahashi H et al Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD) Dig Liver Dis 2008, 40(5):371-378. 10.1016/ j.dld.2007.10.019 18083083
19. Kettaneh A Marcellin P Douvin C Poupon R Ziol M Beaugrand M de Ledinghen V Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients J Hepatol 2007, 46(4):628-634. 10.1016/ j.jhep.2006.11.010 17258346
20. Foucher J Castera L Bernard PH Adhoute X Laharie D Bertet J Couzigou P de Ledinghen V Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations Eur J Gastroenterol Hepatol 2006, 18(4):411-412. 10.1097/ 00042737-200604000-00015 16538113
21. Li LF Dai L Zhang Q Chen YP Feng XR Guo YB Hou JL [Factors influencing the success rate and stability of transient elastography for liver fibrosis evaluation.] Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2008, 28(4):595-597. 18495599
22. Sandrin L Yon S Fournier C Miette V Transient elastography: Changing clinical practice in hepatology The Journal of the Acoustical Society of America 2008, 123(5):3000. 10.1121/1.2932562
23. Sasso M Miette V Sandrin L Improvements in liver diseases evaluation using transient elastography for obese patients The Journal of the Acoustical Society of America 2008, 123(5):3000. 10.1121/1.2932565
24. Sarrias MR Rosello S Sanchez-Barbero F Sierra JM Vila J Yelamos J Vives J Casals C Lozano F A role for human Sp alpha as a pattern recognition receptor J Biol Chem 2005, 280(42):35391-35398. 10.1074/jbc.M505042200 16030018
25. Gangadharan B Antrobus R Dwek RA Zitzmann N Novel serum biomarker candidates for liver fibrosis in hepatitis C patients Clin Chem 2007, 53(10):1792-1799. 10.1373/clinchem.2007.089144 17702858
26. Yoon SH Kim JS Song HH Statistical inference methods for detecting altered gene associations Genome informatics 2003, 14:54-63. 15706520
27. Kim JW Ye Q Forgues M Chen Y Budhu A Sime J Hofseth LJ Kaul R Wang XW Cancer-associated molecular signature in the tissue samples of patients with cirrhosis Hepatology 2004, 39(2):518-527. 10.1002/hep.20053 14768006
28. Steel LF Shumpert D Trotter M Seeholzer SH Evans AA London WT Dwek R Block TM A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma Proteomics 2003, 3(5):601-609. 10.1002/pmic.200300399 12748940
29. Teare JP Sherman D Greenfield SM Simpson J Bray G Catterall AP Murray-Lyon IM Peters TJ Williams R Thompson RP Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis Lancet 1993, 342(8876):895-898. 10.1016/ 0140-6736(93)91946-J 8105167
30. Marchi N Mazzone P Fazio V Mekhail T Masaryk T Janigro D ProApolipoprotein A1: A serum marker of brain metastases in lung cancer patients Cancer 2008, 112(6):1313-1324. 10.1002/cncr.23314 18257091
31. Chau P Fielding PE Fielding CJ Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding Biochemistry 2007, 46(28):8445-8450. 10.1021/bi700028u 17580958
32. Naveau S Poynard T Benattar C Bedossa P Chaput JC Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest Dig Dis Sci 1994, 39(11):2426-2432. 10.1007/BF02087661 7525168
33. Kurokawa Y Matoba R Takemasa I Nakamori S Tsujie M Nagano H Dono K Umeshita K Sakon M Ueno N et al Molecular features of non-B, non-C hepatocellular carcinoma: A PCR-array gene expression profiling study J Hepatol 2003, 39(6):1004-1012. 10.1016/S0168-8278(03)00473-2 14642619
34. Cales P Oberti F Michalak S Hubert-Fouchard I Rousselet MC Konate A Gallois Y Ternisien C Chevailler A Lunel F A novel panel of blood markers to assess the degree of liver fibrosis Hepatology 2005, 42(6):1373-1381. 10.1002/hep.20935 16317693